$50.68
Price
$2.9B
Market Cap
—
P/E Ratio
12.0
Forward P/E
$-0.68
EPS (TTM)
—
Dividend Yield
$309M
Cash
$41M
Total Debt
58M
Shares Out
$29.16
$59.68
52-Week Range
Institutional Ownership of SUPERNUS PHARMACEUTICALS INC
|
Fund / Manager
Click to search
|
Shares | Value | % of Portfolio | Cost Basis | Est. Return |
|---|---|---|---|---|---|
|
Third Avenue Management|Matthew Fine
|
189.5K | $9M | $31.09 | +57.93% |
Trading Activity for SUPERNUS PHARMACEUTICALS INC
|
Fund / Manager
Click to search
|
Action | Change | Shares After | Value | Price |
|---|---|---|---|---|---|
| 2024-Q3 | |||||
| BUY | +0.2% | 189.5K | $6M | $31.08 | |
| 2024-Q2 | |||||
| BUY | +18.4% | 189.1K | $5M | $28.97 | |
| 2023-Q4 | |||||
| BUY | +37.0% | 159.7K | $5M | $27.09 | |
| 2023-Q3 | |||||
| BUY | +73.8% | 116.5K | $3M | $30.50 | |
| 2023-Q2 | |||||
| BUY | NEW | 67.1K | $2M | $35.29 | |
| 2022-Q2 | |||||
| BUY | NEW | 2.5K | $72000 | $28.22 | |
Insider Trading for SUPERNUS PHARMACEUTICALS INC
6 Months Insider Sentiment
Buy $0
Sell $1.0M
0
Buys
3
Sells
-1.0M
Net
0
Grants
Largest
$757K
Mottola
$380K
Mottola
$251K
Mottola
| Date |
Insider
Click to search
|
Role
Click to search
|
Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jan 09, 2026 | Frederick M. Hudson | Director | EXERCISE | 15.0K | $12.98 | $195K |
| Dec 19, 2025 | Frank Mottola | SVP, Chief Tech. Ops. Officer | EXERCISE | 5.0K | $39.40 | $197K |
| Dec 19, 2025 | Frank Mottola | SVP, Chief Tech. Ops. Officer | EXERCISE | 15.0K | $25.30 | $380K |
| Dec 19, 2025 | Frank Mottola | SVP, Chief Tech. Ops. Officer | SELL | 5.0K | $50.22 | $251K |
| Dec 19, 2025 | Frank Mottola | SVP, Chief Tech. Ops. Officer | SELL | 15.0K | $50.47 | $757K |
| Dec 18, 2025 | Padmanabh P. Bhatt | Sr. VP of IP, CSO | SELL | 710 | $44.44 | $32K |
| Dec 18, 2025 | Padmanabh P. Bhatt | Sr. VP of IP, CSO | EXERCISE | 1.5K | — | — |
| Nov 21, 2025 | Charles W Newhall III | Director | EXERCISE | 15.0K | $12.98 | $195K |